FWD 2 Commission E: Bugleweed

  The Commission E Monographs

Bugleweed


Lycopi herba
Wolfstrappkraut
Published February 1, 1990

Name of Drug

Lycopi herba, bugleweed, gypsywort.  

Composition of Drug

Bugleweed consists of the fresh or dried, above-ground parts of Lycopus europaeus L.  and/or L.  virginicus L.  [Fam.  Lamiaceae], as well as their preparations in effective dosage.  

The drug contains hydrocinnamic and caffeic acid derivatives, lithospermic acid and flavonoids.  

Uses

Mild thyroid hyperfunction with disturbances of the vegetative nervous system.  

Tension and pain in the breast (mastodynia).  

Contraindications

Thyroid hypofunction, enlargement of the thyroid without functional disorders.  

Side Effects

In rare cases, extended therapy and high dosages of bugleweed preparations have resulted in an enlargement of the thyroid.  Sudden discontinuation of bugleweed preparations can cause increased symptoms of the disease complex.  

Interactions with Other Drugs

None known.  

No simultaneous administration of thyroid preparations.  

Note:Administration of bugleweed preparations interferes with the administration of diagnostic procedures using radioactive isotopes.  

Dosage

The dosage lies between a daily dosage of 1 - 2 g of drug for teas and water-ethanol extracts equivalent of 20 mg of drug.  

Note:Each patient has his own individual optimal level of thyroid hormone.  Only rough estimations of dosage are possible for thyroid disorders, in which age and weight must be considered.  

Mode of Administration

Comminuted herb, freshly pressed juice and other galenical preparations for internal use.  

Actions

Antigonadotropic
Antithyrotropic
Inhibition of the peripheral deiodination of T4
Lowering of the prolactin level